Utility of (18)FLT-PET to Assess Treatment Response in Trastuzumab-resistant and Sensitive HER2-overexpressingHuman Breast Cancer Xenografts

PURPOSE: Evaluate 3’-deoxy-3’-[(18)F]-fluorothymidine ((18)FLT) PET as an early marker of trastuzumab response in HER2-overexpressing xenografts. PROCEDURES: Tumor-to-muscle ratios were compared between both trastuzumab-sensitive and resistant cohorts prior to and after one and two treatments. RESUL...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Imaging Biol
Auteurs principaux: Whisenant, Jennifer G., McIntyre, J. Oliver, Peterson, Todd E., Kang, Hakmook, Sánchez, Violeta, Manning, H. Charles, Arteaga, Carlos L., Yankeelov, Thomas E.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4311727/
https://ncbi.nlm.nih.gov/pubmed/25034624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11307-014-0770-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires